2012 2013 seasonal trivalent inactivated split virion influenza vaccine (Sanofi)
86
Structured Review
Sanofi
2012 2013 seasonal trivalent inactivated split virion influenza vaccine
2012 2013 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+split/influenza+vaccine/pm42167137-59-7-15
Average 86 stars, based on 1 article reviews
2012 2013 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+split/influenza+vaccine/pm42167137-59-7-15
Average 86 stars, based on 1 article reviews
2012 2013 seasonal trivalent inactivated split virion influenza vaccine - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Immunopeptidomics:Article Title: Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial Article Snippet: Coadministration of mRNA-1345 with standard-dose (SD) inactivated influenza vaccine or COVID-19 vaccine (Spikevax, Moderna, Inc.) was previously investigated in adults aged ≥50 y in a phase 3 trial with favorable safety and immunogenicity outcomes. .. Here, we report the primary analyses from a phase 3 trial to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 when coadministered with or given sequentially after Article Title: Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial. Article Snippet: .. Among these, a highdose (HD) inactivated influenza vaccine containing four times the antigen of standard-dose vaccines is approved for individuals aged ≥65 y in various regions and is one of the influenza vaccines preferentially recommended in the United States for this older age group.25–27 Coadministration of mRNA-1345 with standard-dose (SD) inactivated influenza vaccine or COVID-19 vaccine (Spikevax, Moderna, Inc.) was previously investigated in adults aged ≥50 y in a phase 3 trial with favorable safety and immunogenicity outcomes.28 Here, we report the primary analyses from a phase 3 trial to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 when coadministered with or given sequentially after other:Article Title: Serial Cycle Threshold to Assess the Infectious Potential of SARS-CoV-2: A Systematic Review Article Snippet: TJ was a member of an independent data monitoring committee for a Article Title: Serial Cycle Threshold to Assess the Infectious Potential of SARS-CoV-2: A Systematic Review Article Snippet: TJ was a member of an independent data monitoring committee for a Article Title: Insights into the heterogeneity of pneumococcal polysaccharide vaccine immunogenicity in older adults. Article Snippet: All participants received a single intramuscular dose of the PPV23 vaccine (Pneumovax 23©, Merck Sharp & Dohme), often co-administered with the seasonal unadjuvanted quadrivalent inactivated influenza vaccine (QIV) for the Recombinant:Article Title: Preexisting IgG forms immune complexes and links local thermal reactogenicity with immunogenicity in influenza vaccination. Article Snippet: .. We stimulated the cells with 1g/ml recombinant hemagglutinin (A/Brisbane/02/2018 (H1N1) and A/Kansas/14/2017 (H3N2)) (both from (eENZYME LLC, Gaithersburg, MD, USA) or with the commercial Vaccines:Article Title: Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial. Article Snippet: .. Among these, a highdose (HD) inactivated influenza vaccine containing four times the antigen of standard-dose vaccines is approved for individuals aged ≥65 y in various regions and is one of the influenza vaccines preferentially recommended in the United States for this older age group.25–27 Coadministration of mRNA-1345 with standard-dose (SD) inactivated influenza vaccine or COVID-19 vaccine (Spikevax, Moderna, Inc.) was previously investigated in adults aged ≥50 y in a phase 3 trial with favorable safety and immunogenicity outcomes.28 Here, we report the primary analyses from a phase 3 trial to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 when coadministered with or given sequentially after |